It’s really important to consider the data coming from IZALCO and IRAKLIA that are respectively the trials that have shown the non-inferiority of Isa-Pom-Dex and Isa-Kd in subcutaneous versus intravenous. Subcutaneous administration was performed through OBI, that is a dome body injection, a small button, a small tool that we place on the patient’s abdomen and is safe, really fast, and really comfortable...
It’s really important to consider the data coming from IZALCO and IRAKLIA that are respectively the trials that have shown the non-inferiority of Isa-Pom-Dex and Isa-Kd in subcutaneous versus intravenous. Subcutaneous administration was performed through OBI, that is a dome body injection, a small button, a small tool that we place on the patient’s abdomen and is safe, really fast, and really comfortable. So this impacted positively with the adherence and compliance of our patients. The last data showed the patient’s reported outcomes that are absolutely outstanding. And this is in some way in line also with the healthcare professional outcomes that are particularly brilliant in the idea that through OBI we can optimize not only the space in the hospital but also the timing for patients, for healthcare professionals and in some way also for caregivers and for all the team, the entourage that guides the patients in this journey. I think that these data are particularly impactful on our daily practice because we can optimize our outpatient setting and if we consider that inside IRAKLIA there are some patients treated in a domestic setting, I think that we can imagine in a future that I hope that is not so far that we can drive at least the chronic patients after some cycles, hopefully the six cycles of the trial at home. So in the idea that we can in some way fight against a chronic disease, putting the patients in the more comfortable possibilities. So the idea of continuing the treatment at home, that is the best because he can enjoy the loved ones and can enjoy their daily life.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.